Jazz reports three‑year overall‑survival benefit for Ziihera regimens in HER2‑positive gastroesophageal cancer
Jazz Pharmaceuticals presented final Phase 3 HERIZON‑GEA‑01 data showing its bispecific antibody Ziihera (zanidatamab) combined with chemotherapy, with or without tislelizumab, significantly extended overall survival in HER2‑positive advanced gastroesophageal adenocarcinoma. Median overall survival was 27.0 months for Ziihera + tislelizumab + chemo versus 19.6 months for trastuzumab + chemo, a 35% reduction in death risk (HR 0.65). The Ziihera + chemo arm achieved a median overall survival of 22.9 months and a 24% death‑risk reduction (HR 0.76). Approximately 40% of patients receiving Ziihera + tislelizumab + chemo were alive at three years.
Why it matters
The data reinforce Ziihera as the new first‑line HER2‑targeted backbone, likely driving higher adoption and sales of the FDA‑approved regimens. Investors should watch for increased market share versus trastuzumab‑based therapies and potential label expansions.
Key facts
- 1The trial randomized 914 patients at about 225 sites in more than 30 countries. stocktitan.net
- 2Median overall survival was 27.0 months (95 % CI 23.7‑32.2) for Ziihera + tislelizumab + chemo. prnewswire.com
- 3Median overall survival was 19.6 months for trastuzumab + chemo (the comparator). prnewswire.com
- 4Ziihera + tislelizumab + chemo reduced the risk of death by 35 % (HR 0.65; 95 % CI 0.52‑0.80). prnewswire.com
- 5Median overall survival was 22.9 months (95 % CI 19.9‑27.6) for Ziihera + chemo. prnewswire.com
- 6Ziihera + chemo reduced the risk of death by 24 % (HR 0.76; 95 % CI 0.62‑0.93; P=0.0088). prnewswire.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.